中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

13 records (took 0.037 seconds)

    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME
    5.
    发明申请
    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开

    公开(公告)号：US20160368958A1

    公开(公告)日：2016-12-22

    申请号：US15197278

    申请日：2016-06-29

    Applicant: OncoTherapy Science, Inc.

    Inventor： Yusuke NAKAMURA ,  Takuya TSUNODA ,  Ryuji OHSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE

    IPC: C07K14/47 ,  C07K16/18

    CPC classification number: C07K14/4748 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K16/18

    Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

    GENES AND POLYPEPTIDES RELATING TO BREAST CANCERS
    6.
    发明申请
    GENES AND POLYPEPTIDES RELATING TO BREAST CANCERS 审中-公开
    与乳腺癌相关的基因和多肽

    公开(公告)号：US20140228238A1

    公开(公告)日：2014-08-14

    申请号：US14162487

    申请日：2014-01-23

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yusuke NAKAMURA ,  Toyomasa KATAGIRI ,  Shuichi NAKATSURU

    IPC: G01N33/574 ,  C07K16/18 ,  G01N33/50 ,  C07K14/47

    CPC classification number: C07K16/18 ,  A61K31/7088 ,  C07K14/47 ,  C07K14/4748 ,  C12N2310/14 ,  C12Q1/485 ,  G01N33/5011 ,  G01N33/5035 ,  G01N33/57415 ,  G01N2333/9121 ,  G01N2510/00

    Abstract: The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.

    Abstract translation: 本申请提供了新的人类基因A7322，其表达在乳腺癌中显着升高。 本申请还提供了人类基因F3374，其在乳腺癌中的表达显着升高。 由此编码的这些基因和多肽可用于例如乳腺癌的诊断，以及用于开发针对乳腺癌的药物的靶分子。 本发明的特征在于筛选PBK / TOPK的激酶活性的调节剂的方法。 本发明还提供筛选用于预防或治疗癌症（例如乳腺癌）的药剂的方法。

    TMEM22 PEPTIDES AND VACCINES INCLUDING THE SAME
    10.
    发明申请
    TMEM22 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
    TMEM22肽和疫苗，包括它们

    公开(公告)号：US20140199336A1

    公开(公告)日：2014-07-17

    申请号：US14221721

    申请日：2014-03-21

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yusuke NAKAMURA ,  Takuya TSUNODA ,  Ryuji OHSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE

    IPC: C07K7/06

    CPC classification number: C07K7/06 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/57 ,  C07K14/705

    Abstract: Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.

    Abstract translation: 描述了由SEQ ID NO：33的氨基酸序列组成的分离肽或其与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导性的因此适合用于癌症免疫治疗，特别是癌症疫苗的上下文中的其片段 这里。 本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。 还提供了编码任何上述肽的核酸以及包含上述肽或核酸中任何一种的药物，物质和组合物。 本发明的肽，核酸，药物，物质和组合物在癌症和肿瘤的治疗中具有特别的用途。

Patent Agency Ranking